Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease

Kidney International

Volumn 73, Issue 8, 2008, Pages 956-962

  Gutierrez O M ^a   Isakova, T ^a   Andress, D L ^b   Levin, A ^c   Wolf, M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chronic kidney disease; Mineral metabolism; Racial disparities

Indexed keywords

CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 41449084839     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.4     Document Type: Article

References (52)

1. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
2. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
3. Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis 1998; 32: S3-S12.
4. Li YC, Kong J, Wei M et al. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
5. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
6. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006; 36(Suppl 2): 51-62.
7. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237.
8. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
9. Giachelli CM, Jono S, Shioi A et al. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001; 38: S34-S37.
10. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), CaxPO(4), and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
11. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
12. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
13. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
14. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
15. Dawson-Hughes B. Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. Am J Clin Nutr 2004; 80: 1763S-1766S.
16. Nesby-O'Dell S, Scanlon KS, Cogswell ME et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002; 76: 187-192.
17. Bell NH, Greene A, Epstein S et al. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985; 76: 470-473.
18. Gupta A, Kallenbach LR, Zasuwa G et al. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 2000; 11: 330-334.
19. Sawaya BP, Butros R, Naqvi S et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 2003; 64: 737-742.
20. De Boer IH, Gorodetskaya I, Young B et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-2769.
21. Cooper L. USRDS. 2001 Annual Data Report. Nephrol News Issues 2001; 15: 31, 34-35, 38 passim.
22. McClellan W, Warnock DG, McClure L et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. J Am Soc Nephrol 2006; 17: 1710-1715.
23. Xue JL, Eggers PW, Agodoa LY et al. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries. J Am Soc Nephrol 2007; 18: 1299-1306.
24. National Kidney Foundation. K/DOQI guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S52-S57.
25. Martinez I, Saracho R, Montenegro J et al. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29: 496-502.
26. Pitts TO, Piraino BH, Mitro R et al. Hyperparathyroidism and 1, 25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67: 876-881.
27. Wilson L, Felsenfeld A, Drezner MK et al. Altered divalent ion metabolism in early renal failure: role of 1, 25(OH)2D. Kidney Int 1985; 27: 565-573.
28. Fajtova VT, Sayegh MH, Hickey N et al. Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 1995; 57: 329-335.
29. Sondik EJ, Lucas JW, Madans JH et al. Race/ethnicity and the 2000 census: implications for public health. Am J Public Health 2000; 90: 1709-1713.
30. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
31. Schwarz S, Trivedi B, Kalanter-Zadeh K et al. Association of disorders of mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 825-831.
32. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
33. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
34. Lind L, Hanni A, Lithell H et al. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995; 8: 894-901.
35. Poole KE, Loveridge N, Barker PJ et al. Reduced vitamin D in acute stroke. Stroke 2006; 37: 243-245.
36. Wang T, Pencina M, Booth S et al. Vitamin D deficiency and the risk of cardiovascular disease. Circulation 2008; 117: 503-511.
37. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
38. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
39. Zittermann A, Schleithoff SS, Tenderich G et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-112.
40. Weishaar RE, Kim SN, Saunders DE et al. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990; 258: E134-E142.
41. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026-1033.
42. Arnaud CD. Hyperparathyroidism and renal failure. Kidney Int 1973; 4: 89-95.
43. Chen RA, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004; 286: F1005-F1011.
44. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2007: advance online publication 13 June 2007 (DOI:10.1038/sj.ki.5002287).
45. Fuleihan GE, Gundberg CM, Gleason R et al. Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 1994; 79: 1642-1647.
46. Cosman F, Morgan DC, Nieves JW et al. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12: 958-966.
47. Fulgoni III V, Nicholls J, Reed A et al. Dairy consumption and related nutrient intake in African-American adults and children in the United States: continuing survey of food intakes by individuals 1994-1996, 1998, and the National Health And Nutrition Examination Survey 1999-2000. J Am Diet Assoc 2007; 107: 256-264.
48. Bryant RJ, Wastney ME, Martin BR et al. Racial differences in bone turnover and calcium metabolism in adolescent females. J Clin Endocrinol Metab 2003; 88: 1043-1047.
49. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637-1647.
50. Need AG, Horowitz M, Morris HA et al. Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women. Am J Clin Nutr 2000; 71: 1577-1581.
51. Martins D, Wolf M, Pan D et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007; 167: 1159-1165.
52. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.